Scimitar Equity Blog

BCLI.OB announced that it has entered into agreements with 3 investors with each investing $500 K for a total of investment of $1.5 M with issuance to each of 3 investors,  2 M shares of stock based on the 30 day average share price as of 2/11/10 of $0.25 per share and 1 M warrants with an exercise price of $0.50 per share for a total issuance of 6 M shares and 3 M warrants.  Read more…

The objective of the filed IND Application is to start a Phase I/II study at multiple centers. The study would involve the use of retinal cells, which have been developed from the stem cells of the embryo for the treatment of patients suffering Stargardt’s Macular Dystrophy (SMD).

Read more…

The resulting effect of the reverse stock split is that every 8 shares of the issued/outstanding common stock prior to the opening of trading will be combined into 1 issued without any change in the par value of shares with the number of authorized but unissued shares of the common stock proportionally reduced. As a result, ASTM (D) could have approximately (rough calculation) 30 M shares outstanding with a total fully diluted value of 40 M including warrants and options.

Read more…

ASTM continues its cardiovascular clinical programs and expects to aggressively to advance these programs in 2010. Net loss was $4.575 M or $.03 per share. Read more…

International Stem Cell Corporation (NASDAQ:ISCO.OB) is a biotech focused on therapeutic and research products.

• ISCO.OB develops pluripotent stem cells that are comparable in function to embryonic stem cells from which cells for human transplant are derived; and techniques to cause those cells to be differentiated into the specific cell types required for transplant, as well as manufactures protocols to produce these cells without contamination with animal by-products.

Focus: ISCO.OB creates human cells for the treatment diabetes, liver disease, corneal disease, and retinal disease through cell transplant therapy, as well as engages in the development of therapeutic products. Read more…

ReNeuron is a UK-based stem cell company. Their primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. RENE.L’s shares are traded on the London AIM market.

Read more…

MultiCell Immunotherapeutics specializes in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery by leveraging patented technology and expertise to develop therapeutics to treat serious diseases including multiple sclerosis, type-1 diabetes, and infectious disease.

Read more…

The public offering/ financing further strengthened its’ balance sheet and to complete ongoing Phase II clinical trials:

• Receiving approximately $12.4 M from the sale of units including the over-allotment,
• The 52,077,100 units consisted of 52,077,100 shares of common stock, Class A Warrants to purchase an aggregate of 39,057,825 shares of common stock and Class B Warrants to purchase an aggregate of 26,038,550 shares of common stock, Read more…

Updating our Cytori Therapeutics blogs of 11/3/09 and 11/10/09 …  Read more…

Referencing our previous 2 blogs; I thought I would back-up my posts with a few stem cell topic definitions (1 of 3 blogs); these were  extrapolated from various websites and a sector report I have put together as well as excerpts from the International Society for Stem Cell Research.

What are stem cells?

Read more…